)
Cytek Biosciences (CTKB) investor relations material
Cytek Biosciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company achievements and market position
Recognized as a leading cell analysis company, named among the fastest growing by TIME and awarded for innovation and drug discovery solutions in 2025.
Shipped over 3,400 instruments to more than 2,000 unique customers in 70+ countries since 2016.
2024 and preliminary 2025 revenue reached $201 million, with $262 million in cash and marketable securities as of September 2025.
Revenue distribution: 50% U.S., 26% EMEA, 24% APAC/ROW; 59% from biotech/pharma/distribution, 41% from academia/government.
Market opportunity projected to grow from $5.1 billion in 2025 to $9.2 billion by 2032 at 8.8% CAGR.
Business pillars and technology innovation
Five business pillars: instruments, applications, bioinformatics, clinical, and services.
Continuous investment in instrument performance, intelligence, and data harmonization.
Cytek Cloud user base grew 40% in 2025, surpassing 22,600 users and supporting automated panel design.
Clinical instruments approved in China and Europe, with improved sensitivity for MRD applications.
AI-driven data analysis and harmonization enhance clinical and research applications.
Product portfolio and growth drivers
Broad portfolio includes conventional, full spectral, and imaging-based flow cytometry tools.
Aurora Evo, launched in 2024, offers high throughput and advanced features, driving replacement cycles.
Reagent business expanded post-2021 acquisition of Tonbo; 2024 reagent revenue grew over 20%, and Q3 2025 reagent revenue grew ~21%.
Acquired Luminex assets in 2023 to enter imaging space and formed partnerships with Bio-Rad and Luminex.
Service and reagent revenue, plus APAC instrument sales, comprise 50% of business and grew double digits in 2024; recurring revenue base continues to expand.
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRI
Net loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high. - 6 FebCRI
Net loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway. - 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRI
Revenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Cytek Biosciences earnings date
Next Cytek Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)